MedPath

Impact of diuretics use in long-term management of congestive heart failure patients to prevent re-hospitalization using the Diagnosis Procedure Combination Database

Not Applicable
Conditions
Heart failure
Registration Number
JPRN-UMIN000046107
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department
Brief Summary

In this study, compared to loop diuretics, additional tolvaptan treatment was not shown to be effective for the time to readmission due to heart failure. Re-hospitalization for heart failure has been shown to be associated with age, Na, creatinine, and prescriptions of ACE inhibitors or ARBs and thiazides. On the other hand, additional treatment with tolvaptan was shown to be significantly longer in terms of time to in-hospital death.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
11257
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients younger than 20 years at the time of the second hospitalization for the disease of interest

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of readmissions due to HF and time to readmission during the second post-discharge follow-up period (after 1 year)
Secondary Outcome Measures
NameTimeMethod
In-hospital death
© Copyright 2025. All Rights Reserved by MedPath